Login to Your Account



Clinic Roundup


Wednesday, June 22, 2011
NanoBio Corp., of Ann Arbor, Mich., started a second tolerability and immunogenicity study designed to test and further optimize its nanoemulsion-based intranasal vaccine adjuvant. The Phase Ib study will test the adjuvant combined with Fluzone (Sanofi). Mucosal, systemic humoral and cellular-mediated immune responses will be examined.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription